2B311620-94F3-4B53-B66A-81AC0A32453B
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 5.7490144546649145
- age_years
- 60
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.625
- E2F_TARGETS+0.578
- INTERFERON_ALPHA_RESPONSE+0.562
- INTERFERON_GAMMA_RESPONSE+0.554
- IL6_JAK_STAT3_SIGNALING+0.547
- G2M_CHECKPOINT+0.543
- ANGIOGENESIS+0.526
- MYC_TARGETS_V1+0.507
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.461
- MYC_TARGETS_V2+0.461
Top 10 suppressed
- KRAS_SIGNALING_DN-0.377
- PANCREAS_BETA_CELLS-0.296
- SPERMATOGENESIS-0.180
- BILE_ACID_METABOLISM-0.173
- MYOGENESIS-0.061
- HEME_METABOLISM-0.047
- UV_RESPONSE_DN-0.010
- HEDGEHOG_SIGNALING+0.003
- ESTROGEN_RESPONSE_EARLY+0.012
- WNT_BETA_CATENIN_SIGNALING+0.025
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934874 | — | — | 0.978 |
| 2 | 65F93AB7-AA99-49B5-8D59-7D0DE9CA9E34 | — | — | 0.976 |
| 3 | A678E1E5-E02D-49A1-BB2B-C91A60E6382E | — | — | 0.974 |
| 4 | C33EDB64-C7B9-49A1-AE73-1D293F8522F6 | — | — | 0.972 |
| 5 | SRR934722 | — | — | 0.971 |
| 6 | AF0A7BAA-D031-4C9F-91B7-7034F2C49D72 | — | — | 0.970 |
| 7 | SRR934965 | — | — | 0.969 |
| 8 | 795FBB8C-0E74-477F-AA27-1CE97A4E90B9 | — | — | 0.969 |
| 9 | 9BFF7746-9003-4941-9590-0B813E00B326 | — | — | 0.968 |
| 10 | 30D8578D-0B48-4D03-9E39-6425494ECD5C | — | — | 0.968 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 43 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.625 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.578 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.562 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.554 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.547 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.543 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.526 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.507 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.461 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.461 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.459 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.456 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.446 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.441 | Idelalisib | — uncovered |
| HYPOXIA | 0.440 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.431 | Idelalisib | — uncovered |
| APOPTOSIS | 0.416 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.409 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.394 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.379 | Inavolisib | — uncovered |